What is the recommended oseltamivir (Tamiflu) dosage for children with confirmed or suspected influenza for treatment and prophylaxis?

Oseltamivir (Tamiflu) Dosing in Children

For children ≥12 months, use weight-based dosing: ≤15 kg = 30 mg, >15–23 kg = 45 mg, >23–40 kg = 60 mg, >40 kg = 75 mg, all given twice daily for 5 days; for infants <12 months, use 3 mg/kg (0–8 months) or 3.5 mg/kg (9–11 months) twice daily for 5 days. 1, 2

Treatment Dosing (5 days, twice daily)

Children ≥12 Months (Weight-Based)

• ≤15 kg (≤33 lb): 30 mg orally twice daily = 5 mL of oral suspension (6 mg/mL) 1, 2, 3
• >15–23 kg (>33–51 lb): 45 mg orally twice daily = 7.5 mL of oral suspension 1, 2, 3
• >23–40 kg (>51–88 lb): 60 mg orally twice daily = 10 mL of oral suspension 1, 2, 3
• >40 kg (>88 lb): 75 mg orally twice daily = 12.5 mL of oral suspension 1, 2, 3

Infants <12 Months (Age-Based, mg/kg Dosing)

• Term infants 0–8 months: 3.0 mg/kg per dose twice daily for 5 days 1, 2, 4
• Infants 9–11 months: 3.5 mg/kg per dose twice daily for 5 days 1, 2, 4
• Use a calibrated 3-mL or 5-mL oral syringe for accurate measurement; household spoons must never be used 1, 5

Preterm Infants (Post-Menstrual Age-Based)

• <38 weeks post-menstrual age: 1.0 mg/kg twice daily for 5 days 1, 2, 5
• 38–40 weeks post-menstrual age: 1.5 mg/kg twice daily for 5 days 1, 2, 5
• >40 weeks post-menstrual age: 3.0 mg/kg twice daily for 5 days 1, 2, 5
• Post-menstrual age = gestational age + chronological age; using term-infant dosing in preterm infants causes toxic drug accumulation due to immature renal function 1, 5

Prophylaxis Dosing (10 days, once daily)

Children ≥12 Months

• Use the same weight-based doses as treatment but once daily instead of twice daily for 10 days 1, 2, 3
• ≤15 kg: 30 mg once daily 1, 2
• >15–23 kg: 45 mg once daily 1, 2
• >23–40 kg: 60 mg once daily 1, 2
• >40 kg: 75 mg once daily 1, 2

Infants 3–11 Months

• 3.0 mg/kg once daily for 10 days 1, 2, 5
• Prophylaxis is not recommended for infants <3 months unless the clinical situation is judged critical due to limited safety data 1, 2, 5

Renal Impairment Adjustments

• Creatinine clearance 10–30 mL/min (treatment): Reduce to 30 mg once daily (instead of twice daily) for 5 days 1, 2, 3
• Creatinine clearance 10–30 mL/min (prophylaxis): Either 30 mg once daily for 10 days OR 75 mg every other day for 10 days (5 total doses) 1, 2, 3

Formulation & Administration

• Oral suspension: 6 mg/mL concentration after reconstitution; preferred formulation for infants and young children 1, 5, 3
• Capsules: Available in 30 mg, 45 mg, and 75 mg strengths; can be opened and mixed with sweetened liquid if needed 1, 3
• Administer with food to reduce nausea and vomiting (occurs in ~10–15% of patients) 1, 5, 6
• If commercial suspension is unavailable, pharmacies can compound a 6 mg/mL suspension according to package insert instructions 1, 5

Critical Timing Considerations

• Initiate treatment within 48 hours of symptom onset for maximum effectiveness; starting within 12–24 hours provides substantially greater benefit 1, 2, 5
• Treatment reduces illness duration by approximately 1–1.5 days (26–36% reduction) and lowers risk of complications like acute otitis media by ~44% 5, 6
• Complete the full 5-day course even if symptoms improve earlier to maintain viral suppression and prevent resistance 1, 2

Common Pitfalls to Avoid

• Do NOT use weight-based categorical dosing (≤15 kg = 30 mg) for infants <12 months—that scheme applies only to children ≥12 months; infants require precise mg/kg dosing 1, 5
• Do NOT apply term-infant dosing to preterm infants—post-menstrual age-based dosing is mandatory to prevent toxicity 1, 5
• Do NOT confuse treatment dosing (twice daily) with prophylaxis dosing (once daily) 1, 5
• Do NOT delay therapy while awaiting laboratory confirmation during influenza season in high-risk patients 2, 5
• Do NOT round doses inappropriately—calculate the exact mg/kg dose and measure the corresponding volume precisely 1

Special Populations & Safety

• FDA-approved for treatment in children as young as 2 weeks of age, though may be used from birth (including preterm infants) when benefits outweigh risks 1, 2, 5
• For extremely preterm infants (<28 weeks post-menstrual age), consult a pediatric infectious disease specialist before initiating therapy 1, 5
• Safety profile in infants is comparable to older children when age-appropriate dosing is used 1, 5
• Most common adverse effects are gastrointestinal (nausea, vomiting), typically mild and transient 1, 6, 7